Adverts

Open Access Articles- Top Results for Lafutidine

Lafutidine

</th></tr>
Lafutidine
250px
Systematic (IUPAC) name
2-[(2-furylmethyl)sulfinyl]-N-((2Z)-4-{[4-(piperidin-1-ylmethyl)pyridin-2-yl]oxy}but-2-en-1-yl)acetamide
Clinical data
AHFS/Drugs.com International Drug Names
Oral
Identifiers
118288-08-7 7pxY
A02BA08
PubChem CID 5282136
ChemSpider 4445337 7pxN
UNII 49S4O7ADLC 7pxY
KEGG D01131 7pxY
Chemical data
Formula C22H29N3O4S
431.54 g/mol
 14pxN (what is this?)  (verify)

Lafutidine (INN) is a second generation histamine H2 receptor antagonist having multimodal mechanism of action and used to treat gastrointestinal disorders. It is marketed in Japan and India.

Medical use

Lafutidine is used to treat gastric ulcers, duodenal ulcers, stomal ulcers, wounds in the lining of the stomach associated with acute gastritis and with acute exacerbation of chronic gastritis.[1][2]

Adverse effects

Adverse events observed during clinical trials included constipation, diarrhea, drug rash, nausea or vomiting and dizziness.[2]

Mechanisms of action

Like other H2 receptor antagonists it prevents the secretion of gastric acid.[2] It also activates calcitonin gene related peptide, resulting in the stimulation of nitric oxide (NO) and regulation of gastric mucosal blood flow, increases somatostatin levels also resulting in less gastric acid secretion, causes the stomach lining to generate more mucin, inhibits neutrophil activation thus preventing injury from inflammation, and blocks the attachment of H. pylori to gastric cells.[2]

History

It is marketed in Japan as Stogar by UCB[1] and in India as Lafaxid by Zuventus Healthcare.[2]

References

  1. ^ a b UCB Japan Revised: April 2005 Stogar tablets
  2. ^ a b c d e Zuventus Healthcare Ltd. India Lafaxid tablets